This technology will prove to be extremely valuable in fighting the Multiple Myeloma disease. It has the ability to predict relapse disease potential and patient survival rate.
Guides treatment options.
Multiple Myeloma is a highly prevalent disease accounting for 1-2% of all cancers, with a market size for treatments estimated to grow to $7 billion by 2020. This technology will prove to be extremely valuable in fighting this disease.
Advantages over Current Technologies Include
Ability to predict relapse/refractory disease potential and patient survival rates. Used to guide treatment options.
Potential to serve as a novel disease-specific drug target.
Stage of Development
Broad ranging patent applied for. Seeking co-development partner to advance assay to the market.
This technology is available for licensing.